Enanta

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Enanta and other ETFs, options, and stocks.

About ENTA

Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases.

CEO

Jay R. Luly

CEOJay R. Luly

Employees

145

Employees145

Headquarters

Watertown, Massachusetts

HeadquartersWatertown, Massachusetts

Founded

1995

Founded1995

Employees

145

Employees145

ENTA Key Statistics

Market cap

276.30M

Market cap276.30M

Price-Earnings ratio

-2.10

Price-Earnings ratio-2.10

Dividend yield

—

Dividend yield—

Average volume

139.35K

Average volume139.35K

High today

$13.51

High today$13.51

Low today

$11.60

Low today$11.60

Open price

$11.60

Open price$11.60

Volume

264.67K

Volume264.67K

52 Week high

$36.04

52 Week high$36.04

52 Week low

$8.08

52 Week low$8.08

ENTA News

Yahoo Finance 21h

Enanta Pharmaceuticals, Inc. Q2 2024 Earnings Call Transcript - Yahoo Finance

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q2 2024 Earnings Call Transcript May 6, 2024 Enanta Pharmaceuticals, Inc. isn't one of the 30 most popular stocks am...

Yahoo Finance 2d

Enanta Pharmaceuticals Reports Fiscal Q2 Results: A Closer Look Against Analyst Expectations - Yahoo Finance

Revenue: Reported at $17.1 million for Q2 2024, slightly above estimates of $16.52 million and down from $17.8 million in Q2 2023. Net Loss: Increased to $31.2...

TipRanks 2d

Enanta reports Q2 EPS ($1.47), consensus ($1.33)

Reports Q2 revenue $17.1M, consensus $16.52M. “At Enanta, we are committed to advancing the first antiviral treatment for RSV, and more broadly developing impor...

Analyst ratings

50%

of 8 ratings

Buy

50%

Hold

37.5%

Sell

12.5%

More ENTA News

Yahoo Finance 2d

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Webcast and Conference Call ... - Yahoo Finance

Anticipates Reporting Topline Data from EDP-323 Respiratory Syncytial Virus (RSV) Challenge Study in Q3 2024 and Phase 2 Study of Zelicapavir in Pediatric RSV P...

Yahoo Finance 5d

Strong week for Enanta Pharmaceuticals shareholders doesn't alleviate pain of five-year loss - Yahoo Finance

While it may not be enough for some shareholders, we think it is good to see the Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) share price up 13% in a single quart...